Comparative Pharmacology
Head-to-head clinical analysis: IMPOYZ versus LAZCLUZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPOYZ versus LAZCLUZE.
IMPOYZ vs LAZCLUZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
LAZCLUZE (lazertinib) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that irreversibly binds to and inhibits EGFR tyrosine kinase, including mutant forms with T790M resistance mutations and exon 19 deletions, thereby blocking downstream signaling pathways involved in tumor cell proliferation and survival.
100 mg orally twice daily
20 mg orally once daily with or without food.
None Documented
None Documented
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
The terminal elimination half-life of Lazcluze is approximately 24-30 hours, supporting once-daily dosing with steady-state achieved within 5-7 days.
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Lazcluze is primarily eliminated via biliary excretion into feces, with approximately 70-80% of the administered dose recovered as unchanged drug in feces. Renal elimination accounts for less than 10% of the dose, with less than 1% excreted unchanged in urine.
Category C
Category C
Unknown
Unknown